Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 1790GAHB Shigella Vaccine in Healthy Adults
NCT02017899Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2014
- Primary completion
- Mar 2015
- Modality
- Lipid-based Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GVGH Shigella sonnei 1790GAHB vaccine in shigellosis (6 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Solicited Local Reaction After Any Vaccination, Number of Subjects With Solicited Systemic Reaction After Any Vaccination and 1 more. Started Feb 2014; status: completed.
02
Drugs
GVGH Shigella sonnei 1790GAHB vaccine
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT02017899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017899.